Figure 8.
Transient exposure to ML-60218 can diminish tumour initiation in vivo. (A) Relative changes in normalized expression of the indicated transcripts, as determined by RT-qPCR, when dissociated tumour cells from CRPC patient H455 were treated for 48 hrs with or without 20 μM ML-60218. (B) Percentages of viable cells, as determined using alamar blue, after 2 days exposure of H455 tumour samples to the indicated concentrations of ML-60218. (C) Growth rates of tumours, following injection of 105 H455 cells pre-treated for 48 hrs with (triangles) or without (circles) 20 μM ML-60218 (n = 4 mice per group). The relative value of 100% refers to a volume of ∼50 mm3. (D) Numbers of mice developing tumours after groups of four mice were injected subcutaneously with the indicated numbers of viable H455 tumour cells after 48 h pre-treatment without (con) or with (test) 20 μM ML-60218. Calculated tumour initiation frequencies and percentages of tumour-forming cells are shown for treatment and control arms.